Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVENT-AML: Azacitidine, Venetoclax and Allogeneic NK Cells for AML
NCT05834244Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2023
- Primary completion
- Jun 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK cell therapy (Anhui Provincial Hospital) in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events. Started Oct 2023; status: recruiting.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05834244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834244.